

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. (Currently amended) A composition comprising a MTB39 antigen (SEQ ID NO:12 or 14) or an immunogenic fragment thereof from a *Mycobacterium* species of the tuberculosis complex, and a MTB32A antigen (SEQ ID NO:2 or 4) or an immunogenic fragment thereof from a *Mycobacterium* species of the tuberculosis complex, ~~wherein~~ which comprises at least one amino acid corresponding to position 183 of SEQ ID NO:4 or position 208 of SEQ ID NO:2 in the MTB32A antigen (SEQ ID NO:2 or 4) that has been substituted by a different amino acid.
2. (Original) The composition of claim 1, comprising a MTB39 antigen (SEQ ID NO:12 or 14) or an immunogenic fragment thereof from a *Mycobacterium* species of the tuberculosis complex, and a polypeptide comprising at least 195 amino acids from the N-terminus of a MTB32A antigen (SEQ ID NO:2 or 4) from a *Mycobacterium* species of the tuberculosis complex.
3. (Original) The composition of claim 2, further comprising a polypeptide comprising at least about 132 amino acids from the C-terminus of MTB32A antigen (SEQ ID NO:2 or 4) from a *Mycobacterium* species of the tuberculosis complex.
4. (Currently amended) The composition of ~~claims~~ claim 1, 2, or 3, wherein the antigens are covalently linked, thereby forming a fusion polypeptide.
5. (Previously presented) The composition of claim 4, wherein the fusion polypeptide has the amino acid sequence of MTB59F (SEQ ID NO:20), wherein the amino acid at position 577 has been substituted by a different amino acid.

6. (Canceled)

7. (Original) The composition of claim 4, wherein the fusion polypeptide has the amino acid sequence of MTB72FMutSA (SEQ ID NO:18).

8. (Currently amended) The composition of claim ~~6~~ 7, further comprising BCG.

9. (Currently amended) The composition of claim ~~6~~ 7, further comprising at least one additional antigen from a *Mycobacterium* species of the tuberculosis complex, wherein the antigen is selected from the group consisting of MTB8.4 antigen (SEQ ID NO:22), MTB9.8 antigen (SEQ ID NO:24), MTB9.9 antigen (SEQ ID NO:27), MTB40 antigen (SEQ ID NO:29), MTB41 antigen (SEQ ID NO:31), 38-1 (SEQ ID NO:35), TbRa3 (SEQ ID NO:37), 38 kD (SEQ ID NO:39), DPEP (SEQ ID NO:41), TbH4 (SEQ ID NO:43), DPPD (SEQ ID NO:45), MTB82, Erd14, ESAT-6 antigen (SEQ ID NO:33), MTB85 complex antigen, or  $\alpha$ -crystalline antigen, or an immunogenic fragment thereof.

10. (Currently amended) The composition of claim ~~6~~ 7, further comprising an adjuvant.

11. (Original) The composition of claim 4, wherein the antigens are covalently linked via a chemical linker.

12. (Original) The composition of claim 11, wherein the chemical linker is an amino acid linker.

13. (Previously presented) The composition of claim 1, further comprising at least one additional antigen from a *Mycobacterium* species of the tuberculosis complex, wherein the antigen is selected from the group consisting of MTB8.4 antigen (SEQ ID NO:22), MTB9.8 antigen (SEQ ID NO:24), MTB9.9 antigen (SEQ ID NO:27), MTB40 antigen (SEQ ID NO:29), MTB41 antigen (SEQ ID NO:31), 38-1 (SEQ ID NO:35), TbRa3 (SEQ ID NO:37), 38 kD (SEQ

ID NO:39), DPEP (SEQ ID NO:41), TbH4 (SEQ ID NO:43), DPPD(SEQ ID NO:45), MTB82, Erd14, ESAT-6 antigen (SEQ ID NO:33), MTB85 complex antigen, or  $\alpha$ -crystalline antigen, or an immunogenic fragment thereof.

14. (Original) The composition of claim 1, further comprising an adjuvant.

15. (Original) The composition of claim 14, wherein the adjuvant comprises QS21 and MPL.

16. (Original) The composition of claim 14, wherein the adjuvant is selected from the group consisting of AS2, ENHANZYN, MPL, 3D-MPL, IFA, QS21, CWS, TDM, AGP, CPG, Leif, saponin, and saponin mimetics.

17. (Original) The composition of claim 1, further comprising BCG or pVac.

18. (Original) The composition of claim 1, further comprising an NS1 antigen or an immunogenic fragment thereof.

19. (Original) The composition of claim 1, wherein the *Mycobacterium* species is *Mycobacterium tuberculosis*.

20-69. (Canceled)

70. (Previously presented) An isolated MTB32A polypeptide from a *Mycobacterium* species of the tuberculosis complex, wherein at least one amino acid corresponding to position 183 of SEQ ID NO:4 or position 208 of SEQ ID NO:2 of the MTB32A antigen (SEQ ID NO:2 or 4) has been substituted by a different amino acid.

71. (Canceled)

72. (Previously presented) The polypeptide of claim 70, wherein an alanine residue has been substituted for the serine residue.

73. (Original) A polypeptide of claim 72, wherein the polypeptide comprises an amino acid sequence of SEQ ID NO:6.

74. (Original) A composition comprising the polypeptide of claim 70.

75. (Original) A fusion polypeptide comprising the polypeptide of claim 70.

76-82. (Canceled)

83. (Previously presented) An isolated fusion polypeptide comprising a MTB39 (SEQ ID NO:12 or 14) antigen from a *Mycobacterium* species of the tuberculosis complex, and an antigen comprising at least 195 amino acids from the N-terminus of a MTB32A antigen (SEQ ID NO:2 or 4) from a *Mycobacterium* species of the tuberculosis complex, wherein at least one amino acid corresponding to position 183 of SEQ ID NO:4 or position 208 of SEQ ID NO:2 in the MTB32A antigen (SEQ ID NO:2 or 4) has been substituted by a different amino acid.

84. (Canceled)

85. (Original) The polypeptide of claim 83, wherein an alanine residue has been substituted for the serine residue.

86. (Original) A composition comprising the polypeptide of claim 83.

87. (Original) A fusion polypeptide comprising the polypeptide of claim 83.

88. (Original) A fusion polypeptide comprising an amino acid sequence of SEQ ID NO:18.